← 返回前沿论文

膀胱癌变异型具有共同的侵袭性特征,包括 CA125⁺ 细胞状态与可靶向的 TM4SF1 表达

英文原题:Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression.

查看英文原题

Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression.

PubMed 2025/06/17(内容时间) Nat Commun Q1 · IF 18.1(JCR 2025)

研究概要

组织学变异(HV)亚型膀胱癌是临床侵袭性肿瘤,与常规尿路上皮癌(UC)相比,对标准治疗更具耐药性。

中文摘要

膀胱癌的组织学变异(HV)亚型是临床上具有侵袭性的肿瘤,与常规尿路上皮癌(UC)相比对标准治疗更具耐药性。目前对其生物学差异背后的转录程序知之甚少。在此,我们通过单细胞分析显示,HV具有一种以MUC16(CA125)、MUC4和KRT24表达为特征的肿瘤细胞状态。这种细胞状态在转移灶中富集,预测对化疗高度耐药,并与不良生存相关。我们还发现跨膜蛋白TM4SF1在HV肿瘤细胞中表达富集。针对TM4SF1蛋白工程化的嵌合抗原受体(CAR)T细胞在体外和体内均以TM4SF1表达依赖的方式显示出对膀胱癌细胞系的活性,突显了其作为治疗靶点的潜力。

展开英文摘要原文

Histologic variant (HV) subtypes of bladder cancer are clinically aggressive tumors that are more resistant to standard therapy compared to conventional urothelial carcinoma (UC). Little is known about the transcriptional programs that account for their biological differences. Here we show using single cell analysis that HVs harbor a tumor cell state characterized by expression of MUC16 (CA125), MUC4, and KRT24. This cell state is enriched in metastases, predicted to be highly resistant to chemotherapy, and linked with poor survival. We also find enriched expression of TM4SF1, a transmembrane protein, in HV tumor cells. Chimeric antigen receptor (CAR) T cells engineered against TM4SF1 protein demonstrated in vitro and in vivo activity against bladder cancer cell lines in a TM4SF1 expression-dependent manner, highlighting its potential as a therapeutic target.

论文信息

作者
Yang H、Song H、Yip E、Gilpatrick T、Chang K、Allegakoen P、Lu KL、Hui K
第一作者单位
Department of Urology, University of California San Francisco, San Francisco, CA, USA.United States
通讯作者单位
Department of Urology, University of California San Francisco, San Francisco, CA, USA. franklin.huang@ucsf.edu.United States
期刊
Nature communications2025 Jun 17
原文标识
PubMed 40527915 · DOI 10.1038/s41467-025-59888-8